A new type of malaria vaccine

Preliminary results show that the effectiveness of the R21 vaccine against malaria in young children is as high as 77%, but researchers are still waiting for larger studies.

A vaccine against malaria has shown promise in early clinical trials, which has ignited hope that one day it may prove to be an effective weapon against one of the world's biggest killers of children .

child

In a trial conducted in 450 children aged 5-17 months, the vaccine called R21 was 77% effective in preventing malaria within a year .

prevention

R21 is an improved vaccine that is already being used in a study on hundreds of thousands of children in Malawi, Kenya and Ghana.

The researchers of the research team plan to conduct the R21 test on 4,800 children in a larger trial, which is scheduled to start next week.

Slow progress

Slow progress

Researchers have spent less than a year developing a list of effective vaccines against COVID-19 , but half a century of hard work has not yet produced a vaccine against malaria to meet the effective goals of the World Health Organization.

COVID-19

Both R21 and Mosquirix target malaria parasites during the spore stage of the malaria parasite life cycle (that is, the stage where the malaria parasite enters the human body from the mosquito host).

Both R21 and Mosquirix target malaria parasites during the spore stage of the malaria parasite life cycle (that is, the stage where the malaria parasite enters the human body from the mosquito host).

Lasting effect

Lasting effect

Researchers will also observe how long-lasting the effects of the vaccine are.

After Mosquito, R21 is the closest vaccine candidate to widespread use, but researchers around the world are looking for ways to improve these two vaccines, including targeting proteins expressed at different stages of the malaria parasite's life cycle.

Researchers are looking for ways to vaccinate people using a disabled version of the entire parasite instead of a single protein.

Currently, the results of R21 are encouraging.

Original source

ssrn.

ssrn.
com/sol3/papers.
cfm?abstract_id=3830681" target="_blank" rel="noopener">Datoo, Mehreen S.
and Magloire Natama, Hamtandi and Somé, Athanase and Traoré, Ousmane and Rouamba, Toussaint and Bellamy, Duncan and Yameogo, Prisca and Valia, Daniel and Tegneri, Moubarak and Ouedraogo, Florence and Soma, Rachidatou and Sawadogo, Se and Sorgho, Faizatou and Derra, Karim and Rouamba, Eli and Orindi, Benedict and Ramos-Lopez, Fernando and Flaxman, Amy and Cappuccini, Federica and Kailath, Reshma and Elias, Sean C.
and Mukhopadhyay, Ekta and Noe, Andres and Cairns , Matthew and Lawrie, Alison and Roberts, Rachel and Valéa, Innocent and Sorgho, Hermann and Williams, Nicola and Glenn, Gregory and Fries, Louis and Reimer, Jenny and Ewer, Katie J.
and Shaligram, Umesh and Hill, Adrian VS and Tinto, Halidou, High Efficacy of a Low Dose Candidate Malaria Vaccine, R21 in 1 Adjuvant Matrix-M™,with Seasonal Administration to Children in Burkina Faso (April 20, 2021).
Available at SSRN: https://ssrn.
com/abstract=3830681orhttp://dx.
doi.
org/10.
2139/ssrn.
3830681Datoo, Mehreen S.
and Magloire Natama, Hamtandi and Somé, Athanase and Traoré, Ousmane and Rouamba, Toussaint and Bellamy, Duncan and Yameogo, Prisca and Valia, Daniel and Tegneri, Moubarak and Ouedraogo, Florence and Soma, Rachidatou and Sawadogo, Se and Sorgho, Faizatou and Derra, Karim and Rouamba, Eli and Orindi, Benedict and Ramos-Lopez, Fernando and Flaxman, Amy and Cappuccini, Federica and Kailath, Reshma and Elias, Sean C.
and Mukhopadhyay, Ekta and Noe, Andres and Cairns , Matthew and Lawrie, Alison and Roberts, Rachel and Valéa, Innocent and Sorgho, Hermann and Williams, Nicola and Glenn, Gregory and Fries, Louis and Reimer, Jenny and Ewer, Katie J.
and Shaligram, Umesh and Hill, Adrian VS and Tinto, Halidou, High Efficacy of a Low Dose Candidate Malaria Vaccine, R21 in 1 Adjuvant Matrix-M™,with Seasonal Administration to Children in Burkina Faso (April 20, 2021).
Available at SSRN: https://ssrn.
com/abstract=3830681or  http://dx.
doi.
org/10.
2139/ssrn.
3830681 Leave a message here